Real-world treatment patterns in third-line patients with metastatic renal cell carcinoma (mRCC): The changing landscape in the United States

被引：0
|
作者：
Pal, Sumanta Kumar
Malangone, Elisabetta
Bhurke, Sharvari
Gorritz, Magdaliz
Stern, Lee
Coombs, John
Turnbull, James D.
Wang, Xufang
Liu, Zhimei
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] LA SER Analyt, New York, NY USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Novartis Pharmaceut, Florham Pk, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.390
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
390
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ACTIVITY OF SUNITINIB AS THIRD-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) (JAPAN)
    Nozawa, M.
    Mochida, Y.
    Nishigaki, K.
    Nagae, S.
    Uemura, H.
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (03) : I11 - I11
  • [2] REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HRU) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Bhanegaonkar, A.
    Gauthier, G.
    Kim, R.
    Vekeman, F.
    Dea, K.
    Robitaille, M. N.
    Moyneur, E.
    Liu, F. X.
    [J]. VALUE IN HEALTH, 2020, 23 : S84 - S84
  • [3] Treatment patterns and costs among patients with metastatic renal cell carcinoma (mRCC) in the United States: A real-world study using integrated claims and clinical data
    Hill, Nathan
    Rosenblatt, Lisa
    Yin, Xin
    Haley, Valerie
    Nguyen, Chi
    Barron, John
    Vilanova, David
    George, Saby
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 398 - 398
  • [4] Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
    Shah, Neil J.
    Sura, Sneha
    Shinde, Reshma
    Shi, Junxin
    Perini, Rodolfo F.
    Puneet, Singhal
    Robert, Nicholas J.
    Vogelzang, Nicholas J.
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [5] Targeted treatment beyond third-line in metastatic Renal Cell Carcinoma (mRCC): Single center outcome of 22 patients
    Vallet, S.
    Hoefner, T.
    Pahernik, S.
    Tosev, G.
    Hadaschik, B.
    Duensing, S.
    Hohenfellner, M.
    Jaeger, D.
    Gruellich, C.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 91 - 91
  • [6] REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH METASTATIC RENAL CELL CARCINOMA RECEIVING FIRST-LINE THERAPY IN THE UNITED STATES VETERAN POPULATION
    Bhanegaonkar, A.
    Kim, R.
    Pandya, S.
    Wang, L.
    Krulewicz, S.
    Pennock, G.
    Phatak, H.
    [J]. VALUE IN HEALTH, 2019, 22 : S116 - S116
  • [7] Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
    Lu, Hong-Rui
    Zhu, Peng-Fei
    Deng, Ya-Ya
    Chen, Zhe-Ling
    Yang, Liu
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [8] Real-world treatment modification of first-line axitinib plus pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)
    Zakharia, Y.
    Thomaidou, D.
    Li, B.
    Siu, G.
    Levin, R.
    Vlahiotis, A.
    Zanotti, G.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1423 - S1424
  • [9] US regional practice patterns in metastatic renal cell carcinoma (mRCC) patients: A real-world retrospective analysis
    Pal, Sumanta Kumar
    Gorritz, Magdaliz
    Sherman, Steven A.
    Liu, Zhimei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [10] Outcomes of "real world" treatment for metastatic renal cell carcinoma (mRCC).
    Harrison, Michael Roger
    George, Daniel J.
    Walker, Mark S.
    Hudson, Lori L.
    Chen, Connie
    Korytowsky, Beata
    Stepanski, Edward J.
    Abernethy, Amy P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345